Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.925 ^USD	-4.10%		+10.80%	+55.99%

Apr. 22	Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26	MT
Apr. 05	Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition	CI

Protara Therapeutics, Inc. Reports Unaudited Consolidated Impairment Charges for the Fourth Quarter Ended December 31, 2022

March 08, 2023 at 08:00 am EST

Protara Therapeutics, Inc. reported unaudited consolidated impairment charges for the fourth quarter ended December 31, 2022. For the quarter, the company reported loss on impairment of goodwill of $29,517,000.

Latest news about Protara Therapeutics, Inc.

Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26	Apr. 22	MT
Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition	Apr. 05	CI
Protara Therapeutics, Inc. Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC	Apr. 05	CI
Protara Therapeutics, Inc. Announces Resignation of Jathin Bandari as Chief Medical Officer, Effective April 11, 2024	Mar. 18	CI
Protara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
Proteon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Top Premarket Gainers	Mar. 12	MT
Top Premarket Decliners	Feb. 12	MT
Top Premarket Decliners	Jan. 17	MT
Protara Therapeutics Says 5 of 6 Patients in Dose Escalation Portion of Bladder Cancer Trial Showed Recurrence-Free Survival	Nov. 30	MT
Protara Therapeutics, Inc. Announces Presentation of Additional Encouraging Data from Phase 1A Advanced-1 Trial of Tara-002 in Nmibc At the 24Th Annual Meeting of the Society of Urologic Oncology	Nov. 30	CI
Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $30, Maintains Outperform Rating	Nov. 06	MT
Protara Therapeutics Q3 Loss Widens; Files for $300 Million Mixed-Securities Shelf Registration	Nov. 03	MT
Protara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Proteon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Protara Therapeutics Doses First Patient in Phase 1b/2 Bladder Cancer Trial; Shares Rise	23-09-20	MT
Protara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Proteon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Guggenheim Assumes Protara Therapeutics at Buy With $22 Price Target	23-07-10	MT
Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations	23-05-02	CI
Protara Therapeutics Reports Positive Results From Portion of TARA-002 Trial to Treat Bladder Cancer; Shares Rise	23-04-28	MT
Protara Therapeutics, Inc. Announces Positive Preliminary Data from Advanced-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development	23-04-28	CI

Chart Protara Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Companyâs portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.925 USD

Average target price

27.8 USD

Spread / Average Target

+850.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PROTARA THERAPEUTICS, INC.	+55.99%	60.19M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+0.47%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.96%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs